These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38593212)

  • 1. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.
    Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen Å
    Clin Cancer Res; 2024 Jun; 30(11):2531-2544. PubMed ID: 38593212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
    Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
    Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
    Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
    J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.
    Hammer S; Schlicker A; Zitzmann-Kolbe S; Baumgart S; Hagemann UB; Scholz A; Haendler B; Lejeune P; Karlsson J; Ellingsen C; Hennekes H; Nielsen CH; Juul MU; Mumberg D; Schatz CA
    Clin Cancer Res; 2021 Aug; 27(15):4367-4378. PubMed ID: 34035067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
    Böhnke N; Indrevoll B; Hammer S; Papple A; Kristian A; Briem H; Celik A; Mumberg D; Cuthbertson A; Zitzmann-Kolbe S
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):669-680. PubMed ID: 37882848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals.
    Ndlovu H; Mokoala KMG; Lawal I; Emmett L; Sathekge MM
    PET Clin; 2024 Jul; 19(3):371-388. PubMed ID: 38658230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
    Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
    Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
    Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
    J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First Clinical Results for PSMA-Targeted α-Therapy Using
    Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
    J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
    Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
    Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
    Stangl-Kremser J; Ricaurte-Fajardo A; Subramanian K; Osborne JR; Sun M; Tagawa ST; Bander NH
    Prostate; 2023 Jul; 83(10):901-911. PubMed ID: 36960580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of CD46 targeted alpha theranostics in prostate cancer using
    Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
    Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
    Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
    Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
    Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.
    Stuparu AD; Meyer CAL; Evans-Axelsson SL; Lückerath K; Wei LH; Kim W; Poddar S; Mona CE; Dahlbom M; Girgis MD; Radu CG; Czernin J; Slavik R
    Theranostics; 2020; 10(6):2612-2620. PubMed ID: 32194823
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
    Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
    J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of
    Bobba KN; Bidkar AP; Meher N; Fong C; Wadhwa A; Dhrona S; Sorlin A; Bidlingmaier S; Shuere B; He J; Wilson DM; Liu B; Seo Y; VanBrocklin HF; Flavell RR
    J Nucl Med; 2023 Jul; 64(7):1076-1082. PubMed ID: 37201957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.